The latest announcement is out from NervGen Pharma ( (TSE:NGEN) ).
NervGen Pharma announced that its President & CEO, Mr. Mike Kelly, will present at the Virtual Life Sciences Investor Forum. This event, hosted by OTC Markets Group and VirtualInvestorConferences.com, will take place on March 13, 2025, with opportunities for virtual one-on-one investor meetings. This presentation could enhance NervGen’s visibility among investors and stakeholders, potentially impacting its market positioning positively.
More about NervGen Pharma
NervGen Pharma Corp. is a clinical-stage biotech company focused on developing neurorestorative therapeutics. The company is working on treatments to promote nervous system repair in neurotrauma and neurologic disease settings. Its lead molecule, NVG-291, is in a Phase 1b/2a clinical trial for spinal cord injury, and a new candidate, NVG-300, is being evaluated preclinically for ischemic stroke, ALS, and spinal cord injury.
YTD Price Performance: -15.95%
Average Trading Volume: 60,810
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $136.3M
Learn more about NGEN stock on TipRanks’ Stock Analysis page.